Monday, May 15, 2017 9:32:46 PM
Back when Nathan Harding was CEO, he described the technology like this.
“We were looking at soldiers who carry heavy loads for long periods of time in uncertain conditions. We looked at how difficult it was for load carriage exoskeletons at that time to carry more than just their own power supply. We decided what was really needed was an exoskeleton architecture that distributed weight down to the ground without consuming any power to do so. That was novel. It meant that power could be used for other things, like helping a soldier walk, rather than holding up the load. Our first prototype of that technology consumed three orders of magnitude less power than the system before it. That innovation built our reputation and gave us the opportunity to help people walk who couldn’t.”
...
So he was saying his system is 1000 times more efficient (physics people say 3 orders of magnitude to describe this) than the previous competitor when it came out. This is largely possible because Russ Angold's application of hydraulics whereas most competitors use electromotors. Obviously others are making strides to catch up, but I think it's Ekso that will be able to address the construction market better than competitors based on their understanding of efficiency. I'd also venture so far as to say it's why DARPA selected them for contracts, but this is only a guess.
The amount of physics involved is remarkable. Exoskeletons that do not have a predesigned walking pattern and instead follow human motion must plot trajectories and respond to human movements by sensing and reacting hundreds of times per second (or at least this is true in ekso's case). Furthermore to do it efficiently is an added complexity (so probably automatically repositioning the exoskeleton under the load instead of holding things at high torque angles where the loads are far away from the feet is involved).
Not having the entire structure fall over when stepping on a rock is an added complexity. I can barely even begin to imagine the complexities involved with having super-human capabilities for something like their military grade TALOS contracts. Weighing so much can't make things simple.
Ekso's at the front line solving these problems because of their DARPA contracts. The work they do there will translate into advances in their other products almost certainly. In my view they are the smartest people on the market with the best exoskeleton, even though it may not walk the fastest.
Ekso had a reverse split and a good amount of stock dilution, but overall their debt levels are very low and I don't think their dilution is more than industry norms for high growth companies *although it's been painful*
Their current exoskeleton is probably too expensive to sell in extremely high numbers, but they are working on a next generation home model that will probably be at a much lower cost. I'm pretty confident in the saleability of this product if it's launched in a reasonable amount of time and the company doesn't get delisted from the NASDAQ. That being said, we've only been below $4 for a fairly short amount of time and we're already on CNBC which is helping us recover. I can also see a bunch of events on the horizon which will likely increase share price. For one, the 2017 veterans appropriations bill I've heard will fund fund stroke treatment for veterans and so far Ekso is the only FDA approved exoskeleton for stroke therapy currently - so perhaps it means the government will buy some EKSO's. Another big event on the horizon for me is TALOS release in 2018.
If you want to learn more about TALOS and Warrior Web, look at Ekso's press releases. Here is the most recent one regarding warrior web:
http://ir.eksobionics.com/press-releases/detail/566/ekso-bionics-selected-for-development-of-next-generation
DISCLOSURE: I'm long EKSO.
Recent EKSO News
- Ekso Bionics Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/29/2024 08:05:00 PM
- Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal • GlobeNewswire Inc. • 04/12/2024 12:00:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2024 09:14:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:08:54 PM
- Ekso Bionics Reports Record Annual Revenue of $18.3 Million • GlobeNewswire Inc. • 03/04/2024 09:05:00 PM
- Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 05:16:39 PM
- Ekso Bionics Announces $4.6 Million Registered Direct Offering • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 10:23:43 PM
- Ekso Bionics Launches GaitCoach Software for EksoNR • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 01/04/2024 10:05:12 PM
- Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29 • GlobeNewswire Inc. • 11/16/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:13:59 PM
- Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal • GlobeNewswire Inc. • 11/02/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 08:17:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:10:19 PM
- Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38% • GlobeNewswire Inc. • 10/26/2023 08:05:00 PM
- Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023 • GlobeNewswire Inc. • 10/19/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 09:23:17 PM
- Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category • GlobeNewswire Inc. • 09/27/2023 12:00:00 PM
- Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/11/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2023 01:44:10 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM